Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA062412-03
Application #
2103628
Study Section
Special Emphasis Panel (SRC (68))
Project Start
1994-03-25
Project End
1997-12-31
Budget Start
1996-01-01
Budget End
1996-12-31
Support Year
3
Fiscal Year
1996
Total Cost
Indirect Cost

  Institution

Name
University of Texas MD Anderson Cancer Center
Department
Neurology
Type
Other Domestic Higher Education
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030

  Publications

Nghiemphu, Phioanh Leia; Ebiana, Victoria Asuquo; Wen, Patrick et al. (2018) Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02. J Neurooncol 136:79-86
Gilbert, Mark R; Kuhn, John; Lamborn, Kathleen R et al. (2012) Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery. J Neurooncol 106:147-53
Vivanco, Igor; Robins, H Ian; Rohle, Daniel et al. (2012) Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov 2:458-71
Norden, Andrew D; Raizer, Jeffrey J; Abrey, Lauren E et al. (2010) Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol 96:211-7
Raizer, Jeffrey J; Abrey, Lauren E; Lassman, Andrew B et al. (2010) A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol 12:95-103
Raizer, Jeffrey J; Abrey, Lauren E; Lassman, Andrew B et al. (2010) A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. Neuro Oncol 12:87-94
Wen, Patrick Y; Yung, W K Alfred; Lamborn, Kathleen R et al. (2009) Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro Oncol 11:853-60
Guo, Deliang; Prins, Robert M; Dang, Julie et al. (2009) EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Sci Signal 2:ra82
Chang, Susan M; Lamborn, Kathleen R; Kuhn, John G et al. (2008) Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium. Neuro Oncol 10:631-42
Lamborn, Kathleen R; Yung, W K Alfred; Chang, Susan M et al. (2008) Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol 10:162-70

Showing the most recent 10 out of 26 publications